期刊文献+

介入时机与西洛他唑对非ST段抬高型心肌梗死后左心室重构的影响 被引量:3

Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction
原文传递
导出
摘要 目的 探讨非ST段抬高型心肌梗死(NSTEMI)后血浆基质金属蛋白酶(MMP)的变化及经皮冠状动脉介入治疗(PCI)时机、西洛他唑对NSTE MI后左心室重构的影响.方法 连续入选行PCI的NSTEMI患者189例,将其中成功随访的164例患者纳入研究.患者分为早期PCI联合西洛他唑组(A组)、早期PCI组(B组)、延迟PCI联合西洛他唑组(C组)和延迟PCI组(D组).检测各组患者心肌梗死后不同时间血浆MMP-2及MMP-9水平.患者于入院时及PCI术后1年行超声心动图检查.结果 (1)NSTEMI后2 d、4 d、2周和4周,MMP-2水平均为A组低于B组,C组低于D组(均P<0.05).NSTEMI后4 d、2周和4周,MMP-9水平均为A组低于B组,C组低于D组(均P<0.05).(2)随访1年显示,左心室舒张末期容积和左心室射血分数的变化值均为A组低于B组,C组低于D组,B组低于D组(P<0.05或P<0.01).左心室缩短分数、左心室舒张末期内径、左心室后壁厚度、室间隔厚度变化值各组间差异均无统计学意义.结论 早期介入治疗及西洛他唑可以改善左心室重构,西洛他唑对左心室重构的影响可能与抑制MMP有关. Objective To observe the dynamic changes of plasma matrix metalloproteinases (MMPs) and investigate the effect of early or delayed percutaneous coronary intervention (PCI) in the presence or absence cilostazol on left ventricle (LV) remodeling in patients with non-ST elevation myocardial infarction (NSTEMI). Methods One hundred and sixty-four patients undergoing PCI with NSTEMI were randomized to early PCI (PCI within 24 h) group or delayed PCI group (PCI after 36 h), and patients in both group were further assigned to cilostazol or no cilostazol group. Plasma MMP-2 and MMP-9concentrations were measured at 2, 4 days and 2 and 4 weeks after PCI. Left ventricular end-diastolic volume ( LVEDV ), left ventricle ejection fraction ( LVEF), left ventricle posterior wall ( LVPW ) and interventricular septum (IVS) were measured by echocardiography at baseline and 1 year after PCI. Results MMP-2 concentration at 2 weeks after PCI is higher than that at 2, 4 days and 4 weeks after PCI. MMP-9concentration at 4 days is higher than that at 2 days, 2 weeks and 4 weeks after PCI. MMP-2 and MMP-9were significantly lower in cilostazol group compared with that in non-cilostazol group at 4 days, 2 weeks and 4 weeks after NSTEMI ( all P 〈 0. 05 ). Changes of LVEDV and LVEF were significantly less in cilostazol group and early PCI group than that in no cilostazol group and delay PCI group (P〈0.05 or P〈0. 01) at 1year after NSTEMI. Conclusions Early PCI and Cilostazol use are associated with less LV remodeling in patients with NSTEMI. Cilostazol attenuated LV remodeling possibly by reducing concentration of MMP-2and MMP-9 after PCI.
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2010年第10期870-874,共5页 Chinese Journal of Cardiology
基金 基金项目:辽宁省自然科学基金(20082074)
关键词 心肌梗死 心室重构 基质金属蛋白酶类 Myocardial infarction Ventricular remodeling Matrix metalloproteinases
  • 相关文献

参考文献22

  • 1Richards AM,Nicholls MG,Troughton RW,et al.Antecedent hypertension and heart failure after myocardial infarction.J Am Coll Cardiol,2002,39:1182-1188.
  • 2Opic LH,Commerford PJ,Gersh BJ,et al.Controversies in ventricular remodelling.Lancet,2006,367:356-367.
  • 3Dollery CM,Libby P.Atherosclerosis and proteinase activation.Cardiovasc Res,2006,69:625-635.
  • 4Fiotti N,Altamura N,Orlando C,et al.Metalloproteinases-2,-9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.Int J Cardiol,2008,127:350-357.
  • 5Janicki JS,Brower GL,Gardner.JD,et al.The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.Heart Fail Rev,2004,9:33-42.
  • 6Van Horn SE Jr,Maniu CV.Management of non-ST-Segment Elevation Myocardial Infarction.Med Clin North Am,2007,91:683 -700.
  • 7Douglas JS Jr,Holmes DR Jr,Kereiakes DJ,et al.Coronary stent restenosis in patients taeated with cilostazol.Circulation,2005,112:2826-2832.
  • 8Lee SW,Park SW,Kim YH,et al.Drug-eluting stenfing followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients).J Am Coil Cardiol,2008,51:1181-1187.
  • 9柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2136
  • 10Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction.Results of the TIMI Ⅲ B trial.Thrombolysis in myocardial ischemia.Circulation,1994,89:1545-1556.

二级参考文献24

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:193
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2135

同被引文献27

  • 1王守力,韩雅玲,荆全民,王祖禄,王冬梅,邓捷,杨桂棠,于海波.西洛他唑对冠状动脉小血管病变支架术后患者的长期疗效[J].第四军医大学学报,2005,26(11):994-997. 被引量:13
  • 2CHEN Yun-dai, LU Yan-ling, JIN Ze-ning, YUAN Fei and Lü Shu-zhengDepartment of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Sciences,Beijing Institute of Heart, Lung and Blood Vessel, Beijing 100029, China.A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent[J].Chinese Medical Journal,2006(5):360-366. 被引量:15
  • 3芦燕玲,陈韵岱,吕树铮.经皮冠状动脉介入治疗后血小板聚集率高的患者强化抗血小板治疗的研究[J].中华心血管病杂志,2007,35(9):793-796. 被引量:10
  • 4Parikh NI, Gona P, Larson MG, et at. Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart Study[J]. Circulation, 2009, 119: 1203-1210.
  • 5GajarsaJ J, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities[n. Heart Fail Rev, 2011, 16: 13-2l.
  • 6Richards AM, Nicholls MG, Troughton RW, et at. Antecedent hypertension and heart failure after myocardial infarction[J].J Am Coll Cardiol , 2002, 39: 1182-1188.
  • 7Radenkovic S, Brajovic M, Konjevic G, et at. Gelatinases A and B activities in the serum of patients with various coronary artery disease stages[J] . Vojnosanit Pregl , 2010, 67: 825-830.
  • 8Dollery CM, Libby P. Atherosclerosis and proteinase activation[J]. Cardiovasc Res, 2006, 69: 625-635.
  • 9Lindsey ML, GannonJ, Aikawa M, et at. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction[J] ' Circulation, 2002. 105: 753-758.
  • 10Dini FL, Buralli S, Bajraktari G, et at. Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with heart failure and a high prevalence of coronary artery disease[J]. Biomed Pharmacother , 2010,64: 339-342.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部